Literature DB >> 29702430

Metabolic products of the intestinal microbiome and extremes of atherosclerosis.

Chrysi Bogiatzi1, Gregory Gloor2, Emma Allen-Vercoe3, Gregor Reid4, Ruth G Wong2, Bradley L Urquhart5, Vincent Dinculescu6, Kelsey N Ruetz5, Thomas J Velenosi5, Michael Pignanelli7, J David Spence8.   

Abstract

BACKGROUND AND AIMS: There is increasing awareness that the intestinal microbiome plays an important role in human health. We investigated its role in the burden of carotid atherosclerosis, measured by ultrasound as total plaque area.
METHODS: Multiple regression with traditional risk factors was used to identify three phenotypes among 316/3056 patients attending vascular prevention clinics. Residual score (RES; i.e. the distance off the regression line, similar to standard deviation) was used to identify the 5% of patients with much less plaque than predicted by their risk factors (Protected, RES <-2), the 90% with about as much plaque as predicted (Explained, RES -2 to 2), and the 5% with much more plaque than predicted (Unexplained RES >2). Metabolic products of the intestinal microbiome that accumulate in renal failure - gut-derived uremic toxins (GDUT) - were assayed in plasma by ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry.
RESULTS: Plasma levels of trimethylamine n-oxide (TMAO), p-cresyl sulfate, p-cresyl glucuronide, and phenylacetylglutamine were significantly lower among patients with the Protected phenotype, and higher in those with the Unexplained phenotype, despite no significant differences in renal function or in dietary intake of nutrient precursors of GDUT. In linear multiple regression with a broad panel of risk factors, TMAO (p = 0.011) and p-cresyl sulfate (p = 0.011) were significant independent predictors of carotid plaque burden.
CONCLUSIONS: The intestinal microbiome appears to play an important role in atherosclerosis. These findings raise the possibility of novel approaches to treatment of atherosclerosis such as fecal transplantation and probiotics.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Intestinal microbiome; Renal impairment; Resistant atherosclerosis; TMAO

Mesh:

Year:  2018        PMID: 29702430     DOI: 10.1016/j.atherosclerosis.2018.04.015

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  36 in total

Review 1.  The Bridge Between Ischemic Stroke and Gut Microbes: Short-Chain Fatty Acids.

Authors:  Zongwei Fang; Mingrong Chen; Jiafen Qian; Chunhua Wang; Jinhua Zhang
Journal:  Cell Mol Neurobiol       Date:  2022-03-28       Impact factor: 5.046

Review 2.  The role of the gut microbiota in health and cardiovascular diseases.

Authors:  Lu Wang; Shiqi Wang; Qing Zhang; Chengqi He; Chenying Fu; Quan Wei
Journal:  Mol Biomed       Date:  2022-10-11

3.  Heterogeneity in statin responses explained by variation in the human gut microbiome.

Authors:  Tomasz Wilmanski; Sergey A Kornilov; Christian Diener; Matthew P Conomos; Jennifer C Lovejoy; Paola Sebastiani; Eric S Orwoll; Leroy Hood; Nathan D Price; Noa Rappaport; Andrew T Magis; Sean M Gibbons
Journal:  Med (N Y)       Date:  2022-05-11

Review 4.  The role of chronic kidney disease-associated dysbiosis in cardiovascular disease.

Authors:  Mark A Bryniarski; Fares Hamarneh; Rabi Yacoub
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-25

5.  Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk.

Authors:  Yoriko Heianza; Wenjie Ma; Joseph A DiDonato; Qi Sun; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi
Journal:  J Am Coll Cardiol       Date:  2020-02-25       Impact factor: 24.094

6.  Gestational age-dependent development of the neonatal metabolome.

Authors:  Madeleine Ernst; Simon Rogers; Ulrik Lausten-Thomsen; Anders Björkbom; Susan Svane Laursen; Julie Courraud; Anders Børglum; Merete Nordentoft; Thomas Werge; Preben Bo Mortensen; David M Hougaard; Arieh S Cohen
Journal:  Pediatr Res       Date:  2020-09-17       Impact factor: 3.756

7.  Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function: A Systematic Review and Meta-Analysis.

Authors:  Yan Zeng; Man Guo; Xia Fang; Fangyuan Teng; Xiaozhen Tan; Xinyue Li; Mei Wang; Yang Long; Yong Xu
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

8.  Exploration of Crucial Mediators for Carotid Atherosclerosis Pathogenesis Through Integration of Microbiome, Metabolome, and Transcriptome.

Authors:  Lei Ji; Siliang Chen; Guangchao Gu; Jiawei Zhou; Wei Wang; Jinrui Ren; Jianqiang Wu; Dan Yang; Yuehong Zheng
Journal:  Front Physiol       Date:  2021-05-24       Impact factor: 4.566

Review 9.  Sex differences in the intestinal microbiome: interactions with risk factors for atherosclerosis and cardiovascular disease.

Authors:  Shamon Ahmed; J David Spence
Journal:  Biol Sex Differ       Date:  2021-05-17       Impact factor: 5.027

10.  Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice.

Authors:  Rostyslav Bubnov; Lidiia Babenko; Liudmyla Lazarenko; Maryna Kryvtsova; Oleksandr Shcherbakov; Nadiya Zholobak; Olga Golubnitschaja; Mykola Spivak
Journal:  EPMA J       Date:  2019-10-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.